{"id":8094,"date":"2020-05-28T14:18:00","date_gmt":"2020-05-28T12:18:00","guid":{"rendered":"https:\/\/primaderma.ro\/?page_id=8094"},"modified":"2020-06-24T11:09:39","modified_gmt":"2020-06-24T09:09:39","slug":"prof-univ-dr-iulia-popescu","status":"publish","type":"page","link":"https:\/\/pdi.ro\/2020\/prof-univ-dr-iulia-popescu\/","title":{"rendered":"Prof. Univ. Dr. Iulia Popescu"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; fullwidth=&#8221;on&#8221; disabled_on=&#8221;on|off|off&#8221; _builder_version=&#8221;3.22&#8243; custom_margin=&#8221;||&#8221; custom_padding=&#8221;15px||29px&#8221; top_divider_style=&#8221;waves2&#8243; top_divider_color=&#8221;#f0622a&#8221; top_divider_flip=&#8221;horizontal|vertical&#8221; bottom_divider_style=&#8221;waves2&#8243; bottom_divider_color=&#8221;#fcdedb&#8221; bottom_divider_height=&#8221;105px&#8221; bottom_divider_flip=&#8221;vertical&#8221; collapsed=&#8221;off&#8221;][et_pb_fullwidth_header title=&#8221;@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@&#8221; text_orientation=&#8221;right&#8221; header_image_url=&#8221;https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/05\/pdi_iulie_online.png&#8221; disabled_on=&#8221;on|on|off&#8221; _builder_version=&#8221;4.4.7&#8243; _dynamic_attributes=&#8221;title&#8221; title_font=&#8221;Kaushan Script||||||||&#8221; title_text_align=&#8221;right&#8221; title_text_color=&#8221;#f0622a&#8221; title_font_size=&#8221;50px&#8221; content_font=&#8221;|600||on|||||&#8221; content_text_align=&#8221;center&#8221; content_text_color=&#8221;#686766&#8243; content_font_size=&#8221;15px&#8221; subhead_font=&#8221;||||||||&#8221; background_color=&#8221;rgba(239,145,107,0.54)&#8221; background_image=&#8221;https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/02\/back.jpg&#8221; background_layout=&#8221;light&#8221; custom_margin=&#8221;0px||8px&#8221; custom_padding=&#8221;40px||40px||true&#8221; content_font_size_tablet=&#8221;&#8221; content_font_size_phone=&#8221;15px&#8221; content_font_size_last_edited=&#8221;on|desktop&#8221;][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22&#8243; locked=&#8221;off&#8221;][et_pb_row column_structure=&#8221;2_5,3_5&#8243; _builder_version=&#8221;3.25&#8243;][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/05\/Popescu-Iulia.jpg&#8221; title_text=&#8221;Popescu Iulia&#8221; align=&#8221;center&#8221; align_tablet=&#8221;center&#8221; align_phone=&#8221;&#8221; align_last_edited=&#8221;on|desktop&#8221; _builder_version=&#8221;4.4.7&#8243; max_width=&#8221;31%&#8221; border_radii=&#8221;on|100px|100px|100px|100px&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.4.7&#8243;]<\/p>\n<h4><strong><span style=\"color: #ff6600;\"><\/span><\/strong><\/h4>\n<h4><strong><span style=\"color: #ff6600;\"><\/span><\/strong><\/h4>\n<h4><strong><span style=\"color: #ff6600;\"><\/span><\/strong><\/h4>\n<h4><strong><span style=\"color: #ff6600;\">Prof. Univ. Dr. Iulia Popescu<\/span><\/strong><br \/><strong><span style=\"color: #ff6600;\">Allergy and Critical Care Division, Department Medicine, University of Pittsburgh, Pittsburgh, PA<\/span><\/strong><\/h4>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=&#8221;3.25&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.4.8&#8243; hover_enabled=&#8221;0&#8243;]<!--\n\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\">Impaired Cytomegalovirus Immunity in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients with Short Telomeres<\/span><br \/> <span style=\"color: #ff6600;\">Authors: <span> I.\u00a0<\/span>Popescu,<span> H.<\/span> Mannem,<span> S.A.<\/span> Winters,<span> A.<\/span>\u00a0Hoji,<span> F.<\/span> Silveira,<span> E.<\/span> McNally,<span> M.R.<\/span> Pipeling,<span> E.A.<\/span> Lendermon,<span> M.R.<\/span> Morrell,<span> J.M.<\/span> Pilewski,<span> V.S.<\/span> Hanumanthu,<span> Y.<\/span> Zhang,<span> S.<\/span> Gulati,<span> P.D.<\/span> Shah, <span> C.J.\u00a0<\/span>Iasella,<span> C.R.<\/span> Ensor,<span> M.<\/span>\u00a0Armanios,<span> J.F.<\/span> McDyer<\/span><\/p>\n\n\n\n\n<p style=\"text-align: justify;\">RATIONALE: Cytomegalovirus (CMV)-related morbidities remain one of the most common complications after lung transplantation and have been linked to allograft dysfunction, but the factors that predict high risk for CMV complications and effective immunity are incompletely understood.<br \/> OBJECTIVES: To determine if short telomeres in idiopathic pulmonary fibrosis (IPF) lung transplant recipients (LTRs) predict the risk for CMV-specific T-cell immunity and viral control.<br \/> METHODS: We studied IPF-LTRs (n\u2009=\u200942) and age-matched non-IPF-LTRs (n\u2009=\u200942) and assessed CMV outcomes. We measured lymphocyte telomere length and DNA sequencing, and assessed CMV-specific T-cell immunity in LTRs at high risk for CMV events, using flow cytometry and fluorescence in situ hybridization.<br \/> MEASUREMENTS AND MAIN RESULTS: We identified a high prevalence of relapsing CMV viremia in IPF-LTRs compared with non-IPF-LTRs (69% vs. 31%; odds ratio, 4.98; 95% confidence interval, 1.95-12.50; P\u2009&lt;\u20090.001). Within this subset, IPF-LTRs who had short telomeres had the highest risk of CMV complications (P\u2009&lt;\u20090.01) including relapsing-viremia episodes, end-organ disease, and CMV resistance to therapy, as well as shorter time to viremia versus age-matched non-IPF control subjects (P\u2009&lt;\u20090.001). The short telomere defect in IPF-LTRs was associated with significantly impaired CMV-specific proliferative responses, T-cell effector functions, and induction of the major type-1 transcription factor T-bet (T-box 21;TBX21).<br \/> CONCLUSIONS: Because the short telomere defect has been linked to the pathogenesis of IPF in some cases, our data indicate that impaired CMV immunity may be a systemic manifestation of telomere-mediated disease in these patients. Identifying this high-risk subset of LTRs has implications for risk assessment, management, and potential strategies for averting post-transplant CMV morbidities.<\/p>\n\n--><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\">Short Telomere \u2013 Short CMV Immunity in IPF Lung Transplant <\/span><br \/> <span style=\"color: #ff6600;\">Authors: Iulia Popescu, Joseph Pilewski, Yangze <span>Zhang<\/span>, Carlo Iasella, Mary Armanios, John F. McDyer<\/span><\/p>\n<p style=\"text-align: justify;\">RATIONALE: Cytomegalovirus (CMV)-related morbidities remain one of the most common complications after lung transplantation and have been linked to allograft dysfunction, but the factors that predict high risk for CMV complications and effective immunity are incompletely understood.<br \/> OBJECTIVES: To determine if short telomeres in idiopathic pulmonary fibrosis (IPF) lung transplant recipients (LTRs) predict the risk for CMV-specific T-cell immunity and viral control.<br \/> METHODS: We studied IPF-LTRs (n\u2009=\u200942) and age-matched non-IPF-LTRs (n\u2009=\u200942) and assessed CMV outcomes. We measured lymphocyte telomere length and DNA sequencing, and assessed CMV-specific T-cell immunity in LTRs at high risk for CMV events, using flow cytometry and fluorescence in situ hybridization.<br \/> RESULTS: We identified a high prevalence of relapsing CMV viremia in IPF-LTRs compared with non-IPF-LTRs (69% vs. 31%; odds ratio, 4.98; 95% confidence interval, 1.95-12.50; P\u2009&lt;\u20090.001). Within this subset, IPF-LTRs who had short telomeres had the highest risk of CMV complications (P\u2009&lt;\u20090.01) including relapsing-viremia episodes, end-organ disease, and CMV resistance to therapy, as well as shorter time to viremia versus age-matched non-IPF control subjects (P\u2009&lt;\u20090.001). The short telomere defect in IPF-LTRs was associated with significantly impaired CMV-specific proliferative responses, T-cell effector functions, and induction of the major type-1 transcription factor T-bet (T-box 21;TBX21).<br \/> CONCLUSIONS: Because the short telomere defect has been linked to the pathogenesis of IPF in some cases, our data indicate that impaired CMV immunity may be a systemic manifestation of telomere-mediated disease in these patients. Identifying this high-risk subset of LTRs has implications for risk assessment, management, and potential strategies for averting post-transplant CMV morbidities.<\/p>\n<p><!--\n\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\">Markers of donor-specific allorecognition in lung transplant recipients<\/span><br \/> <span style=\"color: #ff6600;\">Authors: Iulia Popescu, Joseph M. Pilewski, Yangze Zhang, Carlo Iasella, Kong Chen, John F. McDyer<\/span><\/p>\n\n\n\n\n<p style=\"text-align: justify;\">Chronic lung allograft dysfunction-(CLAD) significantly limits long-term survival in lung transplant recipients-(LTRs) and acute cellular rejection-(ACR) are the major risk- factor for CLAD. The immune-mechanisms leading to ACR\/CLAD can be study by characterize and identify the key markers of donor-specific-allorecognition in lung transplant-recipients. Evaluation of donor-specific alloreactive effector lung T-cells bronchoalveolar-lavage-BAL and peripheral blood-mononuclear cells-PBMC via indirect\/and\/direct allorecognition responses in LTRs with\/without histologic evidence of ACR\/and\/CLAD. Alloeffector T-cell responses from LTRs cells in BAL and PBMC, were assessed with ex vivo flow cytometric assay and donor-alloantigen. LTRs ACR (median-4months), and CLAD-developed (median-20months). We study and evaluate effector-responses cytokines along with costimulation surface-molecule-CD154(CD40L) to donor-alloantigen. We measured and evaluate the predominant type of alloeffector cytokine responses between CD8+ and CD4+ T-cells and between tissue compartments with CD154-upregulation. Using single-cell RNAseq analysis we analyzed the transcriptome in response to alloantigen in lung-cells LTRs-CLAD. A prediction of Type-1 alloeffector responses during ACR\/CLAD with high CD154-upregulation marker was predominant in lung cells associated with alloeffector-responses and cytotoxic-CD4+-subset playing an important role. Those studies will delineate novel-biomarkers and targetable-pathways that will contribute to the diagnoses, treatment, and\/or prevention of CLAD, opening lines of novel research in lung transplantation with great innovative clinical potential.<br \/> <img decoding=\"async\" src=\"https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/05\/Lung-allograft.jpg\" \/><br \/> Allograft is a tissue graft from a donor (same species as the recipient) but not genetically-identical. The long term survival in lung transplant recipients-(LTRs) is limited by chronic lung allograft dysfunction-(CLAD). Our aim is to investigate the immune-mechanisms involved in CLAD after lung-transplantation (1). The innate and adaptive immune-reactions induced by the allograft lead to CLAD (multifactorial-disease irreversible and unpredictable). Acute cellular rejection-(ACR) is the major risk factor for CLAD. We study and try to identified key markers of donor-specific-allorecognition in LTRs. Those markers were characterized by ex vivo mixed lymphocytes reaction, mimicking what is happening post-lung-transplantation adding donor cells and alloreactive effector recipient cells. The alloimmunity-immune-response to donor-nonself antigens, was measured using flow cytometry and single cell RNAseq assays. Those studies could delineate novel-biomarkers and targetable-pathways that will contribute to the diagnoses, treatment, prevention of CLAD, opening lines of research novel in lung transplantation with great innovative clinical-potential.<\/p>\n\n--><\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\">Short CV<\/span><\/p>\n<p>I am a Research Assistant Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at the University of Pittsburgh, and I have significant experience in transplant research in basic immunology with a focus on mechanisms of CMV-specific lung mucosal\/systemic immunity and viral control, as well on EBV, showing the important role for the Type-1 transcription factor T-bet and Eomes as well other immune markers. I also have experience in studying T cell mechanisms of allograft rejection\/tolerance in lung transplantation. I am the Co-PI on a U01 award (AI125050) to perform a novel clinical trial to perform tandem lung and bone marrow transplantation in select individuals with primary immunodeficiencies and end-stage lung disease, and to perform mechanistic pathogen-specific and alloimmune tolerance studies in these study participants. I am also a Co-PI on an R01 award HL133184-01, \u201cRole of F-box Proteins in Lung Transplantation.\u201d In my study I\u2019ve focused in viral mucosal immunology, I am the also Co-PI on U01HL121814, \u201cImmune Mechanisms of HIV-associated COPD. In addition, I am the Co-PI in another lung transplant research effort focused on novel drug development for antibody-mediated lung transplant rejection (Amgen). I am the University of Pittsburgh site Co-PI for the R01, \u201cClinical Risk Factors in Primary Graft Dysfunction\u201d (HL087115). I am proficient in measuring lung mucosal and systemic viral-specific and allospecific multifunctional T cell immunity and phenotyping in lung transplant recipients. I have helped in the establishment of an extensive lung transplant tissue biorepository\/registry (BREATHE-LT) that collects and stores BAL fluid\/cells, blood for plasma\/PBMC, bronchial brushes, along with a clinical research database for phenotyping lung transplant recipients and assessing outcomes for translational studies. I am also working as a Co-PI on a current CFF award, \u201cMolecular and Clinical Endotypes in Chronic Lung Allograft Dysfunction\u201d in which RNA sequence analysis of the airway transcriptome and proteomics in ongoing studies in the mechanisms of CLAD. Finally, we have recently reported on the impact of short telomeres in pulmonary fibrosis lung transplant recipients who demonstrate increased CMV complications and impaired viral immunity. Pertinent to this proposal I also have significant experience assessing alloimmunity, using flow cytometry, in addition to viral immunity, and evaluate the phenotype of T cells, proliferation and effector multifunction to measure inflammatory responses, that makes me suited to serve as PI on this Stuart K. Patrick grant.<\/p>\n<p><strong>Positions and Employment<\/strong><br \/> 2014-pres. Research Assistant Professor, Pulmonary, Allergy and Critical Care Division, Department Medicine, University of Pittsburgh, Pittsburgh, PA<br \/> 2012-2014 Research Associate\/Manager Flow Cytometry Core, Pulmonary, Allergy and Critical Care Division, Department Medicine, University of Pittsburgh, Pittsburgh, PA<br \/> 2010-2011 Senior Scientist\/Technical Application Specialist, Cellular Technology Limited, Shaker Heights, OH<br \/> 2006-2010 Faculty Research Instructor, Dept of Surgery Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA<br \/> 2001-2006 Postdoctoral Research Associate, Dept of Surgery Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA<br \/> 2000-2001 Research Scientist, Dept. of Cellular Immunology and Signal Transduction, Center of Immunology, Institute of Virology Bucharest, Romania<br \/> 1997- 2000 Junior Research Scientist, Department Clinical Immunology, Center for Immunology, Bucharest, Romania<br \/> 1997 3 months-Visiting Research PhD, Doctoral Scientist, Cancer Institute, University of Pittsburgh, Pittsburgh, PA.<br \/> 1994-1997 Research Associate &#8211; Dept. of Cellular Immunology and Signal Transduction, Center of Immunology, Institute of Virology, Bucharest, Romania<br \/> 1991-1994 Resident Scientist- Department Clinical Immunology, Center for Immunology, Bucharest, Romania<br \/> 1986-1991 Research Assistant, Department of Interferon Research \/ Immune-modulators, V. Babes Institute, Bucharest, Romania<\/p>\n<p><strong>Memberships<\/strong><br \/> Member &#8211; American Society of Transplantation (AST) 2006-present<br \/> Member &#8211; American Immunology Association (AIA) 2007-present<br \/> Member &#8211; European Association for Cancer Research (EACR) 1998-present<br \/> Member &#8211; Federation of European Biochemical Societies (FEBS) 1990-present<br \/> Member &#8211; Romanian Society of Immunology (SNI) 1986-present<br \/> Member \u2013 International Society of Heart and Lung Transplantation 2019-present<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22&#8243; background_color=&#8221;rgba(117,194,33,0.23)&#8221; background_image=&#8221;https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/02\/back_justflowers_overlay1.png&#8221; background_blend=&#8221;luminosity&#8221; custom_padding=&#8221;54px|0px|0|0px|false|false&#8221; top_divider_style=&#8221;waves2&#8243; top_divider_color=&#8221;#ffffff&#8221; top_divider_height=&#8221;155px&#8221; top_divider_height_tablet=&#8221;&#8221; top_divider_height_phone=&#8221;97px&#8221; top_divider_height_last_edited=&#8221;on|desktop&#8221; bottom_divider_style=&#8221;waves2&#8243; bottom_divider_color=&#8221;#75c221&#8243; bottom_divider_flip=&#8221;vertical&#8221; bottom_divider_height_tablet=&#8221;&#8221; bottom_divider_height_phone=&#8221;59px&#8221; bottom_divider_height_last_edited=&#8221;on|desktop&#8221;][et_pb_row column_structure=&#8221;3_5,2_5&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;61px|0px|69px|0px|false|false&#8221;][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.0.11&#8243; text_font=&#8221;Kaushan Script||||||||&#8221; text_text_color=&#8221;#f0622a&#8221; text_font_size=&#8221;30px&#8221; text_line_height=&#8221;1.2em&#8221; header_font=&#8221;||||||||&#8221; background_layout=&#8221;dark&#8221; text_font_size_tablet=&#8221;&#8221; text_font_size_phone=&#8221;&#8221; text_font_size_last_edited=&#8221;on|desktop&#8221;]<\/p>\n<p>Contacteaz\u0103 operatorul PDI 2020<\/p>\n<p>[\/et_pb_text][et_pb_contact_form email=&#8221;contact@primaderma.ro\/2019&#8243; submit_button_text=&#8221;Trimite mesajul&#8221; _builder_version=&#8221;3.19.4&#8243; title_font=&#8221;||||||||&#8221;][et_pb_contact_field field_id=&#8221;Name&#8221; field_title=&#8221;Nume&#8221; _builder_version=&#8221;3.18.9&#8243; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][et_pb_contact_field field_id=&#8221;Email&#8221; field_title=&#8221;Adresa de e-mail&#8221; field_type=&#8221;email&#8221; _builder_version=&#8221;3.19.4&#8243; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][et_pb_contact_field field_id=&#8221;Message&#8221; field_title=&#8221;Mesajul dvs.&#8221; field_type=&#8221;text&#8221; fullwidth_field=&#8221;on&#8221; _builder_version=&#8221;3.18.9&#8243; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.0.11&#8243; text_font=&#8221;Kaushan Script||||||||&#8221; text_text_color=&#8221;#f0622a&#8221; text_font_size=&#8221;30px&#8221; header_font=&#8221;||||||||&#8221; background_layout=&#8221;dark&#8221;]<\/p>\n<p>Operatorul PDI 2020<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.0.11&#8243; text_font=&#8221;||||||||&#8221;]<\/p>\n<p><span><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/pdi.ro\/2020\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\" width=\"151\" height=\"33\" alt=\"\" class=\"wp-image-774 alignleft size-full\" \/><\/span><\/p>\n<p><span><\/span><\/p>\n<p><span><\/span><\/p>\n<p><span>Adresa: Str. A. Panu nr. 13, Iasi<\/span><br \/> <span>Tel.: 0332.40.88.00-05<\/span><br \/> <span>E-mail: <a href=\"mailto:inscrieri@primaderma.ro\" target=\"_blank\" rel=\"noopener noreferrer\">inscrieri@primaderma.ro<\/a><br \/> <\/span><span>Website:\u00a0<\/span><a href=\"http:\/\/www.eventernet.ro\/\" target=\"Blank\" rel=\"noopener noreferrer\">www.eventernet.ro<\/a><\/p>\n<p>[\/et_pb_text][et_pb_text disabled_on=&#8221;off|off|off&#8221; _builder_version=&#8221;4.0.11&#8243; text_font=&#8221;Kaushan Script||||||||&#8221; text_text_color=&#8221;#f0622a&#8221; text_font_size=&#8221;30px&#8221; header_font=&#8221;||||||||&#8221; background_layout=&#8221;dark&#8221; locked=&#8221;off&#8221;]<\/p>\n<p>Parteneri Media<\/p>\n<p>[\/et_pb_text][et_pb_gallery gallery_ids=&#8221;7203,7204,7232,7231&#8243; fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.0.11&#8243; transform_scale=&#8221;86%|86%&#8221; max_width=&#8221;63%&#8221; auto=&#8221;on&#8221; auto_speed=&#8221;3500&#8243; hover_transition_duration=&#8221;100ms&#8221; hover_transition_delay=&#8221;50ms&#8221; hover_transition_speed_curve=&#8221;ease-in-out&#8221; locked=&#8221;off&#8221;][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prof. Univ. Dr. Iulia PopescuAllergy and Critical Care Division, Department Medicine, University of Pittsburgh, Pittsburgh, PA Short Telomere \u2013 Short CMV Immunity in IPF Lung Transplant Authors: Iulia Popescu, Joseph Pilewski, Yangze Zhang, Carlo Iasella, Mary Armanios, John F. McDyer RATIONALE: Cytomegalovirus (CMV)-related morbidities remain one of the most common complications after lung transplantation and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8094","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/8094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/comments?post=8094"}],"version-history":[{"count":6,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/8094\/revisions"}],"predecessor-version":[{"id":8401,"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/pages\/8094\/revisions\/8401"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2020\/wp-json\/wp\/v2\/media?parent=8094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}